[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100266176":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":35,"centralContacts":40,"locations":50,"responsibleParty":67,"collaborators":10,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":10,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":10,"enrollmentInfo":80,"targetDuration":10,"studyType":83,"phases":10,"briefSummary":84,"conditions":85,"keywords":10,"overallStatus":52,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"CHU de Quebec-Universite Laval","OTHER",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Prediction Group",null,"The women recruited in the biobank through the Prediction Study (NCT02189148) are low-risk pregnant women between 11 and 13 6\u002F7 weeks of gestation (N=7600 maximum).",[13],"Other: Observational",{"label":15,"type":10,"description":16,"interventionNames":17},"PEARL Group","The women recruited in the biobank through the PEARL Study (NCT02379832) are :\n\n1. low-risk pregnant women between 11 and 13 6\u002F7 weeks of gestation (controls, N=45)\n2. pregnant women with diagnosis of preeclampsia between 20 and 41 6\u002F7 weeks of gestation (cases, N=45)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"GAP Group","The women recruited in the biobank through the GAP Trial (NCT02280031) are women pregnant with twins between 11 3\u002F7 and 13 6\u002F7 weeks of gestation(N=50 maximum) randomized for placebo or aspirin.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"PREDICTION 2 Group","The women recruited in the biobank through the Prediction-2 Study (NCT03067298) are nulliparous pregnant women between 14 and 15 6\u002F7 weeks of gestation (N=1000 maximum).",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"HAUPE Study","Women that are at risk of pre-eclampsia and great obstetrical syndroms (elevated maternal age, invitro fertilization, chronic disease) (N=60) and a control group not at risk (N=60)",[13],[31],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Observational","All women of the biobank have provided:\n\n1. blood samples (plasma, serum and Buffy-coat)\n2. urine samples\n3. demographic and clinical data (maternal age, BMI, smoking status, obstetrical and medical history)\n4. mean arterial blood pressure\n5. ultrasound examination (datation of pregnancy at recruitment, uterine arteries doppler, placental volume, nuchal translucency in the majority of the cases)\n6. access to medical record (for pregnancy\u002Fdelivery outcomes, newborn birthweight, gestational age at delivery)",[19,27,15,23,9],[36],{"name":37,"affiliation":38,"role":39},"Emmanuel Bujold, MD, MSc","CHU de Quebec","PRINCIPAL_INVESTIGATOR",[41,46],{"name":37,"role":42,"phone":43,"phoneExt":44,"email":45},"CONTACT","418-525-4444","47530","emmanuel.bujold@crchudequebec.ulaval.ca",{"name":47,"role":42,"phone":43,"phoneExt":48,"email":49},"Sylvie Tapp, MSc","46039","sylvie.tapp@crchudequebec.ulaval.ca",[51],{"facility":38,"status":52,"city":53,"state":10,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","Québec","G1V 4G2","Canada","CA",{"type":58,"coordinates":59},"Point",[60,61],-71.21454,46.81228,{"lat":61,"lon":60},[64,65],{"name":37,"role":42,"phone":43,"phoneExt":44,"email":45},{"name":47,"role":42,"phone":43,"phoneExt":66,"email":49},"46009",{"type":39,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Emmanuel Bujold","Professor","100266176","biobank-on-prematurity-preeclampsia-and-other-pregnancy-complications-100266176",false,"NCT02744365","Biobank on Prematurity, Preeclampsia and Other Pregnancy Complications","Biobank of Data and of Human Biological Samples on Prematurity, Preeclampsia and Other Pregnancy Complications","Inclusion Criteria:\n\n* (specific to each study)\n\nExclusion Criteria:\n\n* pregnant women \\\u003C18 years old at recruitment\n* negative fetal heart at recruitment\n* women not able to provide an informed consent to the study",true,"FEMALE","18 Years",{"count":81,"type":82},7845,"ESTIMATED","OBSERVATIONAL","The Biobank includes data and biological specimens of women from three original studies: 1) First-trimester Prediction of Preeclampsia (PREDICTION Study, NCT02189148), 2) Pre-Eclampsia And growth Retardation, an evaluative Longitudinal study (PEARL Study, NCT02379832), 3) Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial (NCT02280031) and 4)PREDICTION2: Prediction of Preeclampsia and other Pregnancy Complications Following Combined Iterative Screening.",[86,87,88,89],"Preeclampsia","Preterm Birth","Pregnancy Complications","Fetal Anomalies","2022-03-14",{"date":92,"type":93},"2022-03-16","ACTUAL",{"date":95,"type":93},"2015-04",{"date":97,"type":82},"2028-04",{"name":5,"class":6},1]